Incyte (INCY) Stock Forecast & Price Target $97.16 -0.25 (-0.26%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$97.14 -0.02 (-0.03%) As of 05/22/2026 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Incyte - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating HoldBased on 22 Analyst RatingsSell1Hold11Buy10 Based on 22 Wall Street analysts who have issued ratings for Incyte in the last 12 months, the stock has a consensus rating of "Hold." Out of the 22 analysts, 1 has given a sell rating, 11 have given a hold rating, and 10 have given a buy rating for INCY. Consensus Price Target $104.007.04% Upside According to the 22 analysts' twelve-month price targets for Incyte, the average price target is $104.00. The highest price target for INCY is $135.00, while the lowest price target for INCY is $60.00. The average price target represents a forecasted upside of 7.04% from the current price of $97.16. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for INCY and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Incyte and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INCY Analyst Ratings Over TimeTypeCurrent Forecast5/23/25 to 5/23/261 Month Ago4/23/25 to 4/23/263 Months Ago2/22/25 to 2/22/261 Year Ago5/23/24 to 5/23/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy10 Buy rating(s)10 Buy rating(s)9 Buy rating(s)4 Buy rating(s)Hold11 Hold rating(s)10 Hold rating(s)11 Hold rating(s)13 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$104.00$104.89$104.00$73.53Forecasted Upside7.04% Upside9.87% Upside2.65% Upside14.45% UpsideConsensus RatingHoldHoldHoldHold INCY Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History INCY Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Incyte Stock vs. The CompetitionTypeIncyteMedical CompaniesBroader MarketConsensus Rating Score 2.41 2.30 2.52Consensus RatingHoldHoldModerate BuyPredicted Upside7.04% Upside1,714.95% Upside15.09% UpsideNews Sentiment RatingPositive NewsSee Recent INCY NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/21/2026 Sanford C. Bernstein4 of 5 starsJeffrey WalchNot RatedInitiated CoverageMarket Perform$99.00+1.63%5/21/2026 HC Wainwright3 of 5 starsMitchell S.Not RatedReiterated RatingBuy$135.00+39.06%5/21/2026 Citigroup4 of 5 stars Reiterated RatingBuy4/29/2026 OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJay OlsonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetMarket Perform$84.00 ➝ $90.00-7.92%4/29/2026 Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingStephen WilleySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$120.00 ➝ $123.00+25.84%4/1/2026 Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeHold (C+) ➝ Buy (B-)3/25/2026 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAshwani VermaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetNeutral$104.00 ➝ $94.00+1.82%3/24/2026 BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingOverweight3/16/2026 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingFaisal KhurshidSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Hold$120.00 ➝ $94.00+1.58%2/11/2026 Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingVikram PurohitSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet Target$102.00+3.42% Get the Latest News and Ratings for INCY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. 2/11/2026 Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBrian AbrahamsSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetSector Perform$95.00 ➝ $92.00-6.69%2/11/2026 Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDerek ArchilaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetEqual Weight$107.00 ➝ $101.00+2.60%2/6/2026 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAllison BratzelSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$102.00 ➝ $110.00+7.05%1/13/2026 TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingBuy1/8/2026 The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingNeutral$90.00-18.60%12/24/2025 Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSrikripa DevarakondaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet Target$103.00+2.07%12/8/2025 MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSalim SyedSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet TargetNeutral ➝ Outperform$90.00 ➝ $121.00+18.03%11/10/2025 Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeStrong-Buy ➝ Hold11/3/2025 GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMichael SchmidtSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeNeutral ➝ Buy$125.00+33.72%10/9/2025 JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJessica FyeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetNeutral$73.00 ➝ $89.00+4.24%9/4/2025 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingTazeen AhmadSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$90.00 ➝ $104.00+21.54%7/30/2025 BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEvan SeigermanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingUnderperform$52.00 ➝ $60.00-23.13%3/18/2025 William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingY Katherine XuSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/11/2025 Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReni BenjaminSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingMarket Perform1/10/2025 Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEric SchmidtSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingNeutral10/1/2024 Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndy ChenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOutperform$84.00+27.08%8/1/2024 Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetHold$55.00 ➝ $60.00-6.93%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:26 PM ET. INCY Forecast - Frequently Asked Questions What is Incyte's forecast for 2026? According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Incyte is $104.00, with a high forecast of $135.00 and a low forecast of $60.00. Should I buy or sell Incyte stock right now? 22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There is currently 1 sell rating, 11 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares. Does Incyte's stock price have much upside? According to analysts, Incyte's stock has a predicted upside of 7.04% based on their 12-month stock forecasts. Has Incyte been upgraded or downgraded by Wall Street analysts recently? Over the previous 90 days, Incyte's stock had 3 upgrades and 2 downgrades by analysts. What analysts cover Incyte? Incyte has been rated by research analysts at Barclays, Citigroup, HC Wainwright, Jefferies Financial Group, Oppenheimer, Sanford C. Bernstein, Stifel Nicolaus, UBS Group, and Weiss Ratings in the past 90 days. Do Wall Street analysts like Incyte more than its competitors? Analysts like Incyte more than other "medical" companies. The consensus rating score for Incyte is 2.41 while the average consensus rating score for "medical" companies is 2.30. Learn more on how INCY compares to other companies. Stock Forecasts and Research Tools Related Companies AbbVie Stock Forecast Regeneron Pharmaceuticals Stock Forecast Alnylam Pharmaceuticals Stock Forecast Biogen Stock Forecast United Therapeutics Stock Forecast Neurocrine Biosciences Stock Forecast Exelixis Stock Forecast Ionis Pharmaceuticals Stock Forecast Madrigal Pharmaceuticals Stock Forecast BioMarin Pharmaceutical Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Incyte RecommendationsHC WainwrightCitigroupSanford C. BernsteinStifel NicolausOppenheimerWeiss RatingsUBS GroupBarclaysJefferies Financial GroupWall Street ZenWells Fargo & CompanyRoyal Bank Of CanadaMorgan StanleyPiper SandlerTD Cowen This page (NASDAQ:INCY) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
